Status:

COMPLETED

Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula

Lead Sponsor:

United Pharmaceuticals

Conditions:

Cow Milk Allergy

Eligibility:

All Genders

1-36 years

Phase:

PHASE3

Brief Summary

The aim of this study is to assess the hypoallergenicity of a new thickened extensively hydrolyzed formula, in infants with confirmed cow's milk protein allergy assessed through a double blind placebo...

Eligibility Criteria

Inclusion

  • Main Inclusion Criteria:
  • Infants:
  • with cow's milk allergy confirmed by a double-blind food challenge performed in the last 2 months,
  • successfully fed an eviction diet for at least 2 weeks
  • Main Non-inclusion Criteria:
  • Infants:
  • fed with an extensively hydrolyzed formula with no improvement of the symptoms,
  • who refused to drink an extensively hydrolyzed formula anytime prior to inclusion,
  • fed a vegetable based formula
  • fed an amino acid based formula or who should be fed with an amino acid based formula according to recommendations
  • who had an anaphylactic reaction in the past

Exclusion

    Key Trial Info

    Start Date :

    April 1 2016

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 29 2017

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT02711163

    Start Date

    April 1 2016

    End Date

    November 29 2017

    Last Update

    May 15 2018

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Umberto I university hospital

    Roma, Italy